Compatibility «Aprepitant» and «Gestodene+Ethinylestradiol»
Between «Aprepitant» and «Gestodene+Ethinylestradiol» found 2 dangerous and 18 negative interactions, joint admission is not recommended without consulting a doctor.
Interaction tableCompare |
Gestodene+Ethinylestradiol |
✘Aprepitant Analogs | |
✘Gestodene+Ethinylestradiol [Ethinylestradiol and more 1Gestodene] Analogs |
-
Interactions Aprepitant with Gestodene+Ethinylestradiol
-
Dangerous interactions
Aprepitant should not be used simultaneously with pimozide, terfenadine, astemizole and cisapride (see 'Contraindications'), since dose-dependent inhibition of cytochrome P450 CYP3A4 isoenzyme under the influence of aprepitant can lead to increased concentrations of these drugs in plasma and to potentially serious and life-threatening reactions. Inhibition of the CYP3A4 isoenzyme by an aprepitant may lead to an increase in the concentration of these drugs in plasma and to potentially serious and life-threatening phenomena. -
Negative interactions
The effectiveness of oral contraceptives containing ethinyl estradiol/ norethidron during administration and within 28 days after the end of taking aprepitant may be reduced (alternative or backup methods of contraception should be used during treatment with aprepitant and within 1 month after taking the last dose of aprepitant). The effectiveness of hormonal contraceptives during the period of administration and within 28 days after the end of taking the drug Aprepitant may be reduced. Aprepitant is a substrate, a moderate inhibitor (dose-dependent) and an inducer of the CYP3A4 isoenzyme, as well as an inducer of the CYP2C9 isoenzyme. With simultaneous use of aprepitant (at a dose of more than 40 mg or with repeated doses), it can clinically significantly increase plasma concentrations of drugs whose metabolism occurs with the participation of CYP3A4. When using aprepitant in conjunction with chemotherapeutic drugs, the metabolism of which mainly or partially occurs with the participation of CYP3A4 (etoposide, vinorelbine, docetaxel and paclitaxel), the doses of these drugs may not be adjusted. A possible increase in plasma concentrations of midazolam or other benzodiazepines, the metabolism of which is carried out with the participation of CYP3A4 (alprazolam, triazolam), should be taken into account when prescribing these drugs simultaneously. The combined use of aprepitant with drugs that inhibit the activity of CYP3A4 may lead to an increase in the concentration of aprepitant in blood plasma, therefore, it is necessary to prescribe aprepitant with caution in combination with strong CYP3A4 inhibitors (for example, ketoconazole). However, simultaneous administration of aprepitant with moderate CYP3A4 inhibitors (for example, diltiazem) does not cause clinically significant changes in the concentration of aprepitant in blood plasma. Simultaneous administration of aprepitant with drugs that are strong inducers of CYP3A4 (for example, rifampin) may lead to a decrease in the concentration of aprepitant in blood plasma and, thus, to a decrease in its effectiveness. Aprepitant is a substrate, moderate inhibitor and inducer of the CYP3A4 isoenzyme. With simultaneous use, aprepitant, as a moderate inhibitor of the CYP3A4 isoenzyme, can increase the plasma concentration of oral drugs, the metabolism of which occurs under the action of the CYP3A4 isoenzyme. To a lesser extent, aprepitant can increase the plasma concentration of intravenous drugs taken simultaneously, the metabolism of which occurs under the action of the CYP3A4 isoenzyme. Aprepitant should be used with caution in patients receiving concomitant therapy with drugs metabolized mainly through the CYP3A4 isoenzyme and having a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl and quinidine (see 'Special Instructions'). The potential effect of increasing plasma concentrations of midazolam or other benzodiazepines, whose metabolism is carried out through the CYP3A4 isoenzyme (alprazolam, triazolam), should be taken into account when prescribing these drugs with Aprepitant. Simultaneous administration of Aprepitant with drugs that inhibit the activity of the CYP3A4 isoenzyme may lead to an increase in the concentration of aprepitant in plasma. Therefore, it is necessary to use Aprepitant with caution in combination with strong inhibitors of the CYP3A4 isoenzyme (for example, ketoconazole). However, concomitant administration of Aprepitant with moderate inhibitors of the CYP3A4 isoenzyme (for example, diltiazem, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin and protease inhibitors) does not cause clinically significant changes in the concentration of aprepitant in plasma. Simultaneous administration of Aprepitant with drugs that are strong inducers of the CYP3A4 isoenzyme (for example, rifampicin, phenytoin, carbamazepine, phenobarbital) may lead to a decrease in the concentration of aprepitant in plasma and, thus, to a decrease in the effectiveness of Aprepitant. -
No interactions
When using Aprepitant together with chemotherapeutic drugs, the metabolism of which mainly or partially occurs with the participation of the CYP3A4 isoenzyme (etoposide, vinorelbine, docetaxel, ifosfamide, cyclophosphamide, irinotecan and paclitaxel), the doses of these drugs may not be adjusted. -
Unclear interactions
Oral contraceptives.
-
Dangerous interactions
Decoding the colors of interactions and contraindications
Dangerous | — | a pronounced negative interaction or contraindication. |
Negative | — | negative interaction or side effect that may reduce effectiveness. |
Positive | — | the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication of the drug. |
No | — | the drugs do NOT interact, which is separately indicated in the instructions. |
Unclear | — | the system failed to pre-assess the danger. |
Video instruction
Additional information
- Kiberis checks interactions and evaluates drug compatibility online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
- Why do I need to
- Avoid dangerous prescriptions for your patients.
- Check the contraindications.
- Evaluate the safety of therapy in the treatment of children.
- See the compatibility of drugs with alcohol (enter it as a drug).
- Point the doctor to the found interaction - you may need to adjust the therapy.
- The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
- The article is written: artificial intelligence Kiberis
- Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
- Total analyzed: 169,974,420 possible combinations of drugs and their components were found 412,510 interacting combinations.
- Medicine section: Standard evidence-based medicine
- The date of the last update of the interaction database: 2024-05-02
Category - medicine